Develops immunomodulatory treatments using a proprietary enzyme technology platform. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 60% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 60% a year on average.
Sales run at $22.9M a year. A small number, but proof the product has real buyers.
A loss of $55.1M against $22.9M in annual sales.
At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.